The regulatory immediate-early (IE) protein pp89 of murine cytomegalovirus induces CD8+ T lymphocytes that protect against lethal murine cytomegalovirus infection. The IE1 epitope is the only epitope of pp89 that is recognized by BALB/c cytolytic T lymphocytes (CTL). Using synthetic peptides, the optimal and minimal antigenic sequences of the TEl epitope have been defined. To evaluate the predictive value of data obtained with synthetic peptides, recombinant vaccines encoding this single T-celi epitope were constructed using as a vector the hepatitis B virus core antigen encoded in recombinant vaccinia virus. In infected cells expressing the chimeric proteins, only IE1 epitope sequences that were recognized as synthetic peptides at concentrations lower than 10-6 M were presented to CTL. Vaccination of mice with the recombinant vaccinia virus that encoded a chimeric protein carrying the optimal 9-amino-acid TEl epitope sequence elicited CD8+ T lymphocytes with antiviral activity and, furthermore, protected against lethal disease. The results thus show for the first time that recombinant vaccines containing a single foreign nonameric CTL epitope can induce T-lymphocyte-mediated protective immunity.
Antigenic sequences recognized by cytolytic T lymphocytes (CTL) in viral protein antigens can be identified by using synthetic peptides (23; reviewed in reference 22) . Synthetic peptides also permit definition of the minimal and optimal sequences that bind to major histocompatibility complex class I proteins and are recognized by the antigenspecific T-cell receptor. However, the set of peptides naturally produced in virus-infected cells by processing of viral proteins may differ substantially from the optimal sequences defined with synthetic peptides. Presentation to CTL has been shown recently for epitopes of 13 to 22 amino acids (aa) expressed from chimeric proteins synthesized in transfected and infected cells (5, 10, 26) . However, chimeric proteins have failed to induce a T-lymphocyte response in vivo (13) . Knowledge of the features that affect antigenicity and immunogenicity of epitopes expressed from endogenously synthesized proteins is crucial for design of vaccines containing CTL epitopes.
A need for separate epitopes recognized by helper T lymphocytes, the nature of the carrier protein, and the length and antigenic potency of the inserted antigenic sequence itself may affect the immunogenic potential of recombinant vaccines. We have addressed these issues in a herpesvirus model, murine cytomegalovirus (MCMV) infection, in which a protective antiviral immune response mediated by CD8+ T lymphocytes is induced by the nuclear viral phosphoprotein pp89 (11, 17, 18, 20, 25) . An epitope of pp89 that is recognized by CTL clone IEl (15) has been identified and named the TEl epitope (7) . Using synthetic peptides, the optimal antigenic sequence 168-YPHFMPTNL-176 for CTL clone IEl has been defined. Shorter peptides such as PHFMP N and the core HFMPT are also recognized, but their antigenic potencies are 103-and 106-fold lower, respec- tively (19) .
To examine the predictive value of data obtained with synthetic peptides for the construction of recombinant T-cell * Corresponding author. epitope vaccines, we inserted DNA sequences encoding IEl epitope sequences of various lengths and antigenic potencies into different genetic environments. The capacity of the resulting chimeric proteins to elicit an effective in vivo antiviral T-lymphocyte response was studied. Protection against lethal virus challenge was successfully achieved with a chimeric protein containing a single, 9-aa T-cell epitope.
MATERIALS AND METHODS
Mice. BALB/c mice (H-2d haplotype) were bred in our colony under specific-pathogen-free conditions. Cells. Third-passage mouse embryo fibroblasts were used for infection with MCMV to produce target cells and for determination of virus titers. KD2SV, a simian virus 40-transformed kidney fibroblast line established from B10.D2 mice (H-2d haplotype) (14) , was used for infection with recombinant vaccinia viruses to produce target cells.
Viruses. Purified, tissue-culture-grown MCMV of strain Smith (VR-194; American Type Culture Collection, Rockville, Md.) was used for production of target cells, for generation of CTL, and for infection of mice in adoptive transfer experiments. Challenge infection of immunocompetent vaccinated mice was performed with virulent MCMV isolated from the salivary glands of infected mice (11) .
Recombinant vaccinia viruses. The recombinant vaccinia virus MCMV-ieI-VAC encodes pp89 (25) . The recombinant MCMV-ieI(AF)-VAC encodes a deletion mutant of pp89 that lacks amino acids 136 to 249 and therefore does not contain any epitope recognized by BALB/c CTL (7) .
(i) Deletion of TEl epitope pentameric core: A5-mer construct. The nucleotide sequence encoding the IEl epitope core (170-HFMPT-174) was deleted by site-directed mutagenesis in M13mpl9 using the oligonucleotide 5'GCC CTA GAT TTG GGT ACA TG3' and following the procedure described by Zoller and Smith (27) (1) . Recombinant vaccinia viruses were produced as described earlier (25) .
( (20) , and their in vivo antiviral activity was tested by adoptive transfer into sublethally irradiated (5.5 Gy, corresponding to a 50% lethal dose [LD50] over an observation period of 30 days) and MCMV-infected (2 x 105 PFU in the footpad) 9-week-old recipient BALB/c mice as described previously (20) . Twelve fer, MCMV titers in spleens of individual recipient mice were determined.
Protection against lethal challenge infection. Mice were vaccinated i.v. with 108 PFU of recombinant vaccinia viruses, and 3 weeks later, they were challenged i.p. with 3 LD50s of virulent salivary gland-derived MCMV (11) . RESULTS lE1 epitope sequences are essential for recognition of pp89 by BALB/c CTL. To test whether single epitopes recognized by CTL can replace the whole protein for induction of protective immunity in vivo, knowledge of the number of epitopes present in the protein is important. Previous results showed that the region of pp89 between amino acid residues 136 and 249 was required for recognition of the protein by CTL (7) . Although the IEl epitope presented by Ld has been positively identified within this region (6, 7), it was not excluded that other epitopes exist. To detect epitopes besides IEl, a deletion mutant of pp89, named A5-mer, was constructed and recombined into vaccinia virus. This recombinant lacked just the pentameric core HFMPT of the TEl epitope. When it was used to infect target cells expressing all H-2d class I molecules, the mutant protein was not recognized by polyclonal pp89-specific CTL from BALB/c mice primed with the recombinant MCMV-ieI-VAC encoding authentic pp89 (Fig. 1, left panel) . In an attempt to increase the frequency of CTL specific for putative epitopes in the mutant protein, we primed mice with the A5-mer recombinant. As shown in Fig. 1 (right panel) , no CTL that recognized the A5-mer protein or authentic pp89 could be detected. Likewise, in vitro restimulation with the A5-mer recombinant of memory T lymphocytes from mice that were latently infected with MCMV could not be achieved (data not shown). It was thus concluded that IEl epitope sequences are essential for the recognition of pp89 by BALB/c CTL.
A 9-aa IEl epitope sequence is efficiently presented to CTL even after shifting to a different location of pp89. The protective capacity of pp89 is based on the function of CD8+ T lymphocytes (11) . Since IEl is the only epitope recognized by CTL in pp89, it can be expected that it is sufficient for the induction of protective immunity. Before selecting an TEl sequence of a given length for testing this hypothesis, it should be recalled that synthetic TEl epitope sequences of different lengths show considerably different antigenicities for CTL clone IEl (19) . In this respect, BALB/c polyclonal pp89-specific CTL exhibit a fine specificity similar to that of CTL clone TEl, since the synthetic nonapeptide YPHFMPTNL constituted the optimal antigenic peptide, giving half-maximal recognition at a concentration as low as 10-1°M. The synthetic heptapeptide PHFMPTN and the pentapeptide core HFMIT retained antigenicity, being detected at concentrations of 10-6 and 10' M, respectively (data not shown).
These three IEl epitope sequences were chosen to investigate their ability to be presented when expressed from intracellularly synthesized chimeric proteins. To this end, IE1 epitope sequences of 9, 7, and 5 aa were inserted close to the C terminus of deletion mutant AF of pp89, which lacks the original IEl epitope (7) (Fig. 2A) . DNA constructs were confirmed by sequencing (Fig. 2B ) and then recombined into vaccinia virus. Expression of the chimeric proteins was confirmed by Western blot analysis (Fig. 3A) .
Antigenicity of target cells infected with the different recombinants was tested by using pp89-specific polyclonal CTL as effector cells. As shown in Fig. 4A , target cells infected with the recombinant virus encoding the AF/9-mer chimeric protein were recognized by CTL, thus indicating that the TEl epitope was correctly processed and presented even when inserted into a different position of the same protein.
The 7-mer and 5-mer constructs were, however, not recognized (Fig. 4A) . The same conclusion was reached when mice were immunized with the different recombinant viruses and their spleen cells were tested for the presence of pp89-specific CTL after selective in vitro restimulation with MCMV (data not shown). Additional confirmation also came from experiments in which the different recombinants were used for in vitro restimulation of pp89-specific memory CTL (data not shown). From all this evidence, it was concluded that IEl epitope sequences shorter than 9 aa were not detectably presented from chimeric AF proteins, while the 9-mer was presented as efficiently as from the authentic location in pp89.
IE1 epitope is also presented from an unrelated, HBcAgbased chimeric protein. To test the protective capacity of the IEl epitope in the absence of separate potential pp89-derived helper-T-cell epitopes, we inserted IEI sequences of 9 and 7 aa into an unrelated protein, HBcAg. Recombinant vaccinia viruses were produced, and the sequence (Fig. 2) and expression (Fig. 3B ) of the chimeric proteins were confirmed. As with the AF-based recombinants, when recognition by CTL of cells expressing the chimeric proteins was tested, the 9-mer construct was recognized, whereas the 7-mer was not (Fig. 4B) protein but also to an unrelated protein suggested that the requirements for its processing and presentation are not very stringent.
Correlation between antigenic potency of synthetic peptides and recognition by CTL of chimeric proteins expressing IEl epitope sequences. The lack of recognition by CTL of the 5-mer sequence in AF and of the 7-mer sequence in both chimeric proteins tested could be explained either by their lower antigenicity compared with the 9-mer (19) or by their shorter length, which could bring the antigenic core into closer proximity to potentially disturbing amino acid residues derived from the vector. To discriminate between these alternatives, LEl epitope sequences of different lengths and antigenicities were made to reach a common final length of 9 aa by flanking them with alanine residues. Alanine was chosen because it has the shortest side chain among the amino acids. The feasibility of this approach was first tested at the level of synthetic peptides. The sequence A-PHFMPTN-A has the length of the 9-mer but only the 7 aa of the IE1 epitope present in the 7-mer (PHFMPTN). When tested as a synthetic peptide, the alanine-flanked 7-mer had a slightly higher antigenic potency than the original 7-mer. Similarly, the antigenicity of the peptide AA-HFMPT-AA was comparable to that of HFMPT (Table 1) .
Once it was found that flanking alanine residues did not reduce the antigenic properties of IEl synthetic peptides, the alanine-flanked 7-mer and 5-mer sequences were inserted into HBcAg to test whether these sequences could be presented from intracellularly synthesized proteins. Cells infected with the corresponding recombinant vaccinia vi- IEl in a cytolytic assay. Peptide concentration is given in log molar units.
ruses were again not recognized by CTL (Fig. 4C) , even though all inserts were now 9 aa long. Flanking alanine residues did not generally affect intracellular processing or presentation in a negative manner, since a chimeric protein carrying the 9-mer flanked even by five alanines in HBcAg was recognized by CTL to the same extent as was the 9-mer construct (Fig. 4C) . Thus, the short length was not the determining factor for the lack of presentation of TEl 7-mer and 5-mer sequences from intracellularly synthesized chimeric proteins; rather, the lower antigenicity compared with the 9-mer was the deciding factor. Induction of protection in vivo with the nonameric lE1 epitope sequence. Results shown so far indicate that the 9-mer TEl epitope sequence is as antigenic when presented from chimeric proteins as the authentic pp89. We asked whether this similarity also extended to the protective capacity in vivo, that is, whether the recombinant virus encoding the 9-mer in a chimeric protein could be used as an epitope vaccine. To exclude a contribution of MCMV sequences other than the tested TEl epitope, we used the HBcAg-based chimeric protein.
Induction of protective immunity in vivo was tested by priming mice with the different recombinant viruses followed by a challenge with a lethal dose of MCMV (Fig. 5) . A high percentage of animals primed with the recombinant MCMVieI-VAC encoding the whole pp89 protein were protected 80- against death, as described previously (11) . Lack of the IEl epitope pentameric core in the AS-mer recombinant resulted in the complete inability to induce protective immunity, correlating with the lack of recognition by CTL of cells infected with this recombinant virus in vitro. The finding that priming with HBcAg/9-mer conferred protection against lethal challenge with MCMV confirmed that induction of protection was a property of the IE1 epitope and thus showed the potential of the recombinant virus encoding the 9-mer to function as a T-cell epitope vaccine.
The efficacy of the recombinant vaccine was also tested by adoptive transfer of primed T lymphocytes into irradiated and lethally infected recipient mice (Fig. 6 ). This experimental system reflects more closely the clinical situation, in which infection of immunosuppressed patients with human CMV is more relevant than acute infection of immunocompetent individuals with a high dose of virus. In this model, the antiviral activity of transferred CD8+ T lymphocytes from donors primed with MCMV or with pp89 is reflected by a reduction of MCMV titers in different organs of infected recipient mice (11, 20) (Fig. 6 ). As before, removal of the IEl pentameric core prevented induction of antiviral CD8+ T lymphocytes by the AS-mer recombinant. Priming of the donor mice with the vaccinia virus recombinant encoding HBcAg alone did not induce antiviral T lymphocytes either. In contrast, virus titers in the spleens of the infected recipient mice were reduced after transfer of CD8+ T lymphocytes from mice primed with the HBcAg/9-mer recombinant to the same extent as in those mice that had received cells from donors primed with pp89. These results confirm the data from the challenge experiments and, taken together, demonstrate the induction of antiviral CD8+ T lymphocytes and protection against lethal infection by a recombinant vaccine containing a single nonameric T-cell epitope of the MCMV regulatory protein pp89. DISCUSSION CD8+ T lymphocytes mediate protection against lethal MCMV infection after vaccination of mice with a recombinant vaccinia virus encoding a single MCMV gene product, the nonstructural nuclear phosphoprotein pp89, which is expressed in the immediate-early phase of the MCMV replication cycle (11) . In the present report, we extend this finding by showing that a chimeric protein carrying a sequence of only 9 aa, which constitutes the only epitope recognized by BALB/c CTL in pp89, induces a degree of protection similar to that afforded by the entire pp89 protein.
In the lymphocytic choriomeningitis virus model, protection has been recently shown using truncated viral proteins. However, when an isolated CTL epitope was expressed in vaccinia virus, it was recognized in vitro by CTL but failed to induce T cells in vivo. A need for increased epitope expression or additional T-helper epitopes required for CTL induction was postulated (13) . In our case, however, inclusion of separate sequences from pp89 or from any other MCMV protein for recognition by helper T lymphocytes was not required either for the induction or for the antiviral activity of CD8+ T lymphocytes. These results do not indicate any difference in the viral sequence requirements for CTL induction and recognition and thus encourage the design of multivalent vaccines that include short CTL epitopes from several viral proteins, as well as linear epitopes recognized by antibodies. This is the first example of successful induction of protective cellular immunity using as a carrier HBcAg, a protein utilized to date only for the induction of antibodies to foreign epitopes (2) . The finding that a very short sequence of pp89 can substitute for the whole protein opens the possibility of exploring antigen presentation from different carrier vectors, including those with a very limited capacity for insertion of foreign sequences. This possibility is substantiated by the finding that the IEl epitope nonameric sequence was efficiently processed and presented from the two chimeric proteins tested.
To evaluate the antigenicity required from a candidate epitope for a recombinant vaccine, IEl epitope sequences of different lengths and antigenicities were flanked by alanine residues to reach a common final length of 9 aa. The additional flanking alanines apparently did not affect either intracellular processing of chimeric proteins or presentation of synthetic peptides by surface class I molecules. Comparison of IEl sequences of the same length which were inserted into the same genetic environment revealed that the IEl epitope 7-mer (A-PHFMPTN-A) and 5-mer (AA-HFMPT-AA) sequences could not be recognized by CTL when expressed from intracellularly synthesized chimeric proteins, whereas the 9-mer (YPHEMPTNL) was recognized. This correlates with the lower antigenicity of the 7-mer and 5-mer synthetic peptides compared with that of the 9-mer. Thus, only IEl antigenic sequences that as synthetic peptides were recognized at concentrations below 10-6 M were also detectable by CTL when presented from intracellularly synthesized proteins. Moreover, only such sequences could trigger a pp89-specific immune response in vivo. More generally, our results suggest the existence of an antigenicity threshold that must be reached for the presentation of antigenic peptides from intracellularly synthesized proteins. This may explain why some sequences are antigenic as synthetic peptides but are not recognized after intracellular antigen processing in presentation by major histocompatibility complex class I (3) or class II (4, 8) molecules.
The finding that a 9-mer sequence is sufficient for antigen presentation and induction of protective immunity agrees with recent data on naturally processed peptides isolated from virus-infected cells, for which lengths of 8 and 9 aa have been found (21, 24) . We suggest that the information obtained with synthetic peptides concerning the length and the antigenic potency of optimal antigenic sequences may have a predictive value also in other systems for the successful construction of recombinant vaccines containing short CTL epitope sequences.
